The management and treatment of heart failure was revolutionised by the introduction of the thiazide diuretics more than 30 years ago (Slater & Nabarro 1958) . In more recent years, there have been further major changes in therapy due to the improved understanding of the pathophysiology of heart failure, the introduction of new drugs, particularly the angiotensin-converting enzyme (ACE) inhibitors, results from large trials on old drugs such as digoxin, the availability of new techniques for investigation and the emergence of cardiac transplantation as a therapeutic option. The objectives of treatment in heart failure are simply to treat the symptoms and signs, alter the progression of the disease and improve the prognosis. Preliminary data indicate prevention of the disease to be an achievable goal in high risk situations, such as after myocardial infarction (Sharpe et al. 1988 ).
The Traditional Approach
Patients with heart failure are advised not to smoke, to maintain an optimal weight and to limit their intake of salt. However, a low salt diet, which is unpleasant for the patient, is not necessary, because of the availability of modern diuretics. Patients should be encouraged to lead as normal a life as possible and not to restrict their exercise activity. There is some evidence to show that exercise is of benefit to patients with heart failure. There is no place for bed rest, since the purpose of treating heart failure is to improve the initial symptoms of patients and not to further diminish their physical activity. Appropriate preventive measures should be taken if the patient is hypertensive, consumes an excess of alcohol or has coronary artery disease. The treatment of hypertension has had a major impact on the prevalence of heart failure due to chronic hypertension. 20 years ago, almost 75% of heart failure patients (Kannel et al. 1988 ) had a history of hypertension compared with 6% of patients in a recent survey in the United Kingdom.
Initial drug treatment is with a thiazide diuretic. Steps should be taken to avoid the development of hypokalaemia; several approaches are possible. The potassium intake in the diet can be increased; potassium supplements can be given or a potas-sium-sparing diuretic may be added. If the heart failure is of mild or moderate severity, then initial therapy should be with a loop diuretic which is often combined with a potassium-sparing diuretic (Poole-Wilson 1987) . In some countries, digoxin is introduce.d .early,in )he treatment of heart failure. Other physicians reserve the use of digoxin for the treatment of patients in atrial fibrillation. In severe heart failure, the dose of the loop diuretic may be increased, combinations of diuretics can be used and ACE inhibitors can be added to the treatment (Poole-Wilson 1988) . Nowadays, most patients with severe heart failure are treated with diuretics and ACE inhibitors. Other drugs such as nitrates are useful if patients have symptoms at a particular time of day. In patients with end-stage heart failure, many other drugs, including vasodilators, intermittent inotropic drugs, /12-adrenoceptor agonists and phosphodiesterase inhibitors, may be used. In these patients, the prognosis is poor and drugs are used on compassionate grounds.
The Digoxin Controversy
Cardiac glycosides have a long history and reports of their use in medicine exist in Roman literature (Moore 1985) and in Indian descriptions of Ayerdic medicine many centuries BC (Sharma 1986 ). The modern use of digoxin began with the publication of William Withering's celebrated book (1785). Nevertheless, there are few drugs in modern clinical medicine whose use varies so much between countries. The central argument in the current controversy is often misunderstood, particularly by those who favour the continued use of digoxin. If diuretics and other cardiovascular drugs were not available to the modern physician for the treatment of heart failure, then the combination of bed rest and digoxin might be appropriate, even in patients who were in sinus rhythm.
There is no controversy concerning the use of digoxin to control the heart rate of patients with fast atrial fibrillation. However, debate continues as to whether digoxin is of benefit in patients with heart failure in sinus rhythm (Fleiss et al. 1986; Drugs 39 (Suppl. 4) 1990 Poole-Wilson 1984; Poole-Wilson & Robinson in press; Smith 1988).
Some authors have suggested that digoxin has no long term inotropic effect and no lasting clinical value. Recent data indicate that these claims are unfounded. Digoxin does have a long term inotropic effect, even if small, and can be shown to be beneficial in selected patients, particularly if a third heart sound is present and patients are still in fluid overload. Furthermore, since few inotropic drugs are available for the treatment of patients with heart failure, digoxin may be the only practical choice if a physician does insist on the use of such a drug. The charge against digoxin is not the lack of long term effect nor its failure to benefit selected patients, but that it is a redundant drug. There have been 6 properly conducted double-blind trials of digoxin (Captopril-Digoxin Multicenter Research Group 1988; Fleg et al. 1982; German and Austrian Xamoterol Study Group 1988; Guyatt et al. 1988; Lee et al. 1982; Taggart et al. 1983 ), none of which have shown the drug to increase exercise tolerance. Two of the published trials involved large numbers of patients (Captopril-Digoxin Multicenter Research Group 1988; German and Austrian Xamoterol Study Group 1988) . The best case that can be made for digoxin is that it increased the ejection fraction at rest, reduced hospital admissions (CaptoprilDigoxin Multicenter Research Group 1988) and brought about a non-significant increase in exercise time (Captopril-Digoxin Multicenter Research Group 1988; German and Austrian Xamoterol Study Group 1988) . However, no trial showed a statistically significant increase in exercise time, and these data would not result in approval for a new drug by any drug agency. In these 2 large trials, other drugs, namely captopril (Captopril-Digoxin Multicenter Research Group 1988) and xamoterol (German and Austrian Xamoterol Study Group 1988), were shown to improve exercise time compared with placebo. If patients are appropriately treated with diuretics allowing body fluid volumes to normalise (Anand et al. 1989) , the advantage to be gained from digoxin would appear to be small. Other drugs added to diuretics are superior, and the conclusion must be that the use of digoxin is unnecessary and the drug is becoming redundant.
Influence of Drug Treatment on Prognosis (CONSENSUS Trial Study Group 1987)
The CONSENSUS study demonstrated that ACE inhibitors added to diuretics prolonged life in patients with severe heart failure. These patients had a grim prognosis, and although the increase in duration oflife brought about by the ACE inhibitor was inevitably small in absolute terms, it was still highly significant. This trial established for the first time that drugs other than diuretics could prolong life in severe heart failure. There are several theoretical mechanisms by which this might have been brought about, but 2 dominate current debate. The first is that the alteration of central haemodynamics (the vasodilator property of ACE inhibitors) results in the unloading of the ventricle and the delay in progression of disease within the heart muscle itself. If this were the correct mechanism, any vasodilator should have the same effect. A modification of this hypothesis is that ACE inhibitors alter the architecture of the heart by influencing the process of hypertrophy, the development of fibrosis and cell slippage. The second mechanism is that the ACE inhibitors interact with the diuretics in the kidney to control the manifestations of heart failure, the most important being sodium and water retention.
In more mild heart failure, evidence for the prolongation of life by any drug other than diuretics is not as absolute. Prazosin has no effect, but the combination of hydralazine and nitrates (Cohn et al. 1986 ) seems to confer some benefit. There are also indications that ACE inhibitors may prolong life in mild heart failure (Captopril Multicentre Research Group 1983; Kleber 1987). Large trials are currently being undertaken to resolve this issue.
Treatment of Early Heart Failure with ACE Inhibitors
If ACE inhibitors are beneficial in terms of the symptoms and signs of heart failure and longevity in patients with severe heart failure, it is reason-27 able to ask whether these drugs should be used earlier in the treatment of heart failure, and whether results from patients with severe heart failure can be applied to patients with mild or moderate heart failure. Much ofthe stimulation of the renin-angiotensin system in heart failure is a consequence of the use of diuretics (Bayliss et a1. 1987) . It is logical to combine a diuretic with an ACE inhibitor to prevent what may be regarded as a side effect of the use of diuretics. Several clinical trials have indicated that in moderate heart failure, exercise tolerance and the quality of life is improved by ACE inhibitors (Captopril-Digoxin Multicenter Research Group 1988; Captopril Multicentre Research Group 1983; Chalmers et al. 1987; Kleber 1987; Magnani & Magelli 1986) .
By the use of simple clinical criteria, physicians are able to assess the dose of diuretic needed to normalise the body fluid compartments in patients with heart failure due to sodium retention (Anand et al. 1989) . At this point, the physician should consider the use of an ACE inhibitor. At present, many physicians prescribe such drugs only when patients are taking 80mg of frusemide (furosemide). In the future, the use of an ACE inhibitor will probably be considered when the patient is on frusemide 40mg and continues to have symptoms. Eventually, the combination of diuretics and an ACE inhibitor may be the initial treatment of heart failure. The use of an ACE inhibitor alone may be beneficial in preventing some of the consequences after myocardial infarction (Pfeffer et al. 1988; Sharpe et a1. 1988) , but it appears to be unsatisfactory treatment in patients who have experienced heart failure precipitated by sodium retention (Richardson et al. 1987) . Many of these questions will be resolved when large trials currently being undertaken are completed.
Use of New Drugs in Heart Failure
Recent additions to the available treatments include drugs with inotropic properties, specific effects on the kidney, vasodilator properties, and !3-blockers with substantial intrinsic sympathomimetic activity. Xamoterol (German and Aus-trian Xamoterol Study Group 1988) is an example of this latter class of drug and may be useful in patients with so-called diastolic heart failure due to a small heart, ischaemic heart disease and the presence of tachycardia. In the future, it is probable that the treatment of heart failure will be modified more to the causes of heart failure, the nature of the haemodynamic abnormality and to the effect on the function of peripheral body organs.
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